Tractor Supply Celebrates Hometown Heroes Anniversary With Its Largest-Ever Volunteer Event and $1 Million Donation
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Tractor Supply Company (NASDAQ: TSCO), the largest rural lifestyle retailer in the United States, and the Tractor Supply Company Foundation announced today they are donating an additional $1 million in total to charity organizations committed to supporting our nation's military service members, veterans and first responders. The Company and its foundation made an initial $1 million donation in June 2024 to celebrate the launch of its Hometown Heroes initiative, which brings together the Company's efforts to support the selfless men and women who serve America under one banner.
Tractor Supply launched the second year of its Hometown Heroes initiative yesterday with a Back-to-School Brigade® event in partnership with Operation Homefront, one of the program's 10 recipient organizations. More than 250 Team Members, as well as soldiers from the 101st Airborne Division (Air Assault) at Fort Campbell and members of 4-H and FFA gathered at the Company's Store Support Center (SSC) to pack 500 backpacks with school supplies for military children—marking the largest volunteer event ever held by Tractor Supply.
'At Tractor Supply, support for our military service members, veterans, military families and first responders is entrenched in our culture and values,' said Colin Yankee, chief supply chain officer at Tractor Supply and former U.S. Army Captain. 'Many of our Team Members and customers have served our country or communities, and we're proud to stand with them. From charitable giving to hands-on volunteerism, we're committed to showing appreciation for our Hometown Heroes in meaningful ways.'
Tractor Supply and the Tractor Supply Company Foundation have selected 10 nonprofit organizations to receive $100,000 each as part of this year's $1 million donation. They are:
9/11 Day: Inspires millions of Americans to volunteer, donate to charities and perform other good deeds and acts of kindness on September 11 to honor the memory of those killed or injured on 9/11. In addition to the $100,000 donation, Tractor Supply Team Members, including members of the Veterans Team Member Engagement Group, will gather on September 11, 2025, for a day of service. In 2024, more than 100 Team Members joined Tractor Supply President and CEO Hal Lawton to pack thousands of meals for Americans in need.
Bob Woodruff Foundation: Invests in programs that help our service members, veterans, their families and caregivers thrive. Hometown Heroes funding supports the organization's grant-making, research, community-building and public education initiatives to ensure these individuals have stable and successful futures.
Farmer Veteran Coalition: Provides micro grants to veterans who are in their beginning years of farming or ranching. Tractor Supply has partnered with FVC for the last seven years to assist farmer veterans from all branches of service. Through the joint initiative, the Company has provided more than 400 farmer veterans with Tractor Supply gift cards to access supplies, equipment and training to successfully launch their farm businesses.
Folds of Honor: Provides educational scholarships to the families of fallen and disabled service members and first responders.
K9s For Warriors: Fights veteran suicide by providing trained service dogs (many that are rescue animals) to military veterans suffering from PTSD and other traumas. Through this donation, Tractor Supply will sponsor three dogs—Scarlett on behalf of Tractor Supply, named after former Tractor Supply CEO Joe Scarlett; Murphy on behalf of Petsense by Tractor Supply, named after a heroic military veteran; and Rex (Rx) on behalf of Allivet by Tractor Supply.
National Law Enforcement Officers Memorial Foundation (NLEOMF): Honors fallen law enforcement officers, tells the story of American law enforcement and makes it safer for those who serve. In addition to supporting NLEOMF's work in remembering those who have lost their lives protecting our communities and providing best practices to help keep officers safe, Yankee represented Tractor Supply at the 2025 National Law Enforcement Memorial Candlelight Vigil in Washington, D.C., paying tribute to fallen officers from across the country by reading their names aloud.
National Police Dog Foundation: Raises funds for the purchase, training and veterinary care of law enforcement K-9s. Every October 28, National First Responders Day, Tractor Supply stores across the country host police dogs and their handlers for a celebratory demonstration.
National Volunteer Firefighters Council: Provides critical resources, programs, education and advocacy for volunteer fire, EMS and rescue services across the nation. With the ability to balance volunteer firefighting with their work commitment, thousands of Tractor Supply Team Members serve as passionate and dedicated volunteer firefighters within their communities.
Operation Homefront: Provides relief and recurring family support programs and services to help military families overcome short-term difficulties. Operation Homefront is one of Tractor Supply's newly selected Hometown Heroes donation recipients.
Team Rubicon: Serves global communities before, during and after disasters and crises. Tractor Supply first supported the veteran-led humanitarian organization in its recovery efforts following Hurricane Helene in 2024.
The Hometown Heroes initiative also includes:
A Spotlight Series that recognizes Team Members who embody the spirit of being Hometown Heroes with a $5,000 donation made to a Hometown Hero charity of their choice.
The Neighbor's Club Hometown Heroes benefit, which includes automatic top-tier Preferred Plus Neighbor status, where veterans, service members and first responders are eligible to enroll. This Hometown Heroes benefit is one of the few recognition programs that provide everyday savings with no limit on total savings and no brand exclusions.
To learn more, visit TractorSupply.com/honoringheroes.
About Tractor Supply Company
For more than 85 years, Tractor Supply Company (NASDAQ: TSCO) has been passionate about serving the needs of recreational farmers, ranchers, homeowners, gardeners, pet enthusiasts and all those who enjoy living Life Out Here. Tractor Supply is the largest rural lifestyle retailer in the U.S., ranking 296 on the Fortune 500. The Company's more than 52,000 Team Members are known for delivering legendary service and helping customers pursue their passions, whether that means being closer to the land, taking care of animals or living a hands-on, DIY lifestyle. In store and online, Tractor Supply provides what customers need – anytime, anywhere, any way they choose at the low prices they deserve.
As part of the Company's commitment to caring for animals of all kinds, Tractor Supply is proud to include Petsense by Tractor Supply, a pet specialty retailer, and Allivet, a leading online pet pharmacy, in its family of brands. Together, Tractor Supply is able to provide comprehensive solutions for pet care, livestock wellness and rural living, ensuring customers and their animals thrive. From its stores to the customer's doorstep, Tractor Supply is here to serve and support Life Out Here.
As of March 29, 2025, the Company operated 2,311 Tractor Supply stores in 49 states and 206 Petsense by Tractor Supply stores in 23 states. For more information, visit www.tractorsupply.com and www.Petsense.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the American Diabetes Association (ADA) annual conference in Chicago as part of the symposium, 'Innovation and Progress in Stem Cell-Derived Islet-Cell Replacement Therapy,' from 6:15-6:30 p.m. CT (abstract 2025-A-1921) and published online by the New England Journal of Medicine. The data are from 12 patients who received the full dose of zimislecel as a single infusion and were followed for at least one year, as of October 2024. Results from the study to date continue to demonstrate the transformative potential of zimislecel with consistent and durable patient benefit with longer follow-up. All 12 participants: Demonstrated engraftment with glucose-responsive endogenous C-peptide production, which was durable through one year of follow-up. Achieved the ADA targets of HbA1c <7% and time in range of >70%. Were free of SHEs from day 90 onwards. Had a reduction in exogenous insulin use (mean reduction in daily insulin dose: 92%). 10/12 (83%) no longer required exogenous insulin at Month 12. Achieved the Phase 1/2 primary endpoint of elimination of SHEs with HbA1c <7%. Zimislecel continues to be generally well tolerated. Most adverse events (AEs) were mild or moderate, and there were no serious AEs related to zimislecel treatment. As previously reported, two patient deaths occurred, both unrelated to treatment with zimislecel. The safety profile is generally consistent with the immunosuppressive regimen used in the study, the infusion procedure, and complications from long-standing diabetes. 'These data on the first fully differentiated, stem cell-derived, off-the-shelf islet cell therapy continue to be unprecedented. The magnitude, consistency and durability of the results from all 12 patients with more than one year of follow-up reinforce the transformative potential of zimislecel for people living with T1D complicated by severe hypoglycemia,' said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. 'We are excited to complete enrollment and dosing in the Phase 1/2/3 Program and look forward to potential regulatory submissions next year.' 'It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control by both HbA1c and time in range as well as elimination of severe hypoglycemic events,' said Michael R. Rickels, M.D., M.S., Medical Director, Pancreatic Islet Cell Transplant Program, Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases, Presenting Author and Steering Committee Co-Chair for the zimislecel clinical program, and author on the New England Journal of Medicine paper. 'As I think about my patients and the unmet need in the type 1 diabetes community, the results we've seen so far for restoring endogenous insulin secretion with a stem cell-derived islet therapy bring me hope and confidence for a transformative treatment option for individuals with type 1 diabetes in the not-so-distant future.' About Type 1 Diabetes T1D results from the autoimmune destruction of insulin-producing beta cells in pancreatic islets. Insulin deficiency results in hyperglycemia and can lead to acute life-threatening complications such as diabetic ketoacidosis. People with T1D are reliant on lifelong treatment with exogenous insulin that requires careful monitoring of blood glucose levels. Even with the availability of advanced exogenous insulin delivery and glucose monitoring systems, people with T1D can have periods of very low and very high blood sugar levels. Exogenous insulin has a narrow therapeutic range and carries an inherent risk of causing low blood sugar levels or hypoglycemic events, which can potentially result in arrhythmias, seizures, coma and even death. Due to the limitations and complexities of exogenous insulin treatment, it can be difficult for people with T1D to achieve and maintain good glucose control. Exposure to prolonged periods of high blood glucose levels, or hyperglycemia, can lead to long-term complications such as nerve damage, kidney disease/failure, eye disease (including vision loss), cardiovascular disease, stroke and even death. HbA1c is a measure of average blood glucose over the most recent ~2-3 months, and the consensus guidance is to maintain an HbA1c of <7% to reduce the risk of long-term complications; only ~1 in 4 people with T1D globally meet this clinical target. Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There is no cure for T1D. About Zimislecel Zimislecel (VX-880) is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. Zimislecel is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. Zimislecel has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. Zimislecel is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. The zimislecel trial has expanded to additional sites that are currently active and enrolling in the U.S., Canada and Europe. Zimislecel has been granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration, Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and has secured an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Zimislecel is investigational and has not been approved by health authorities globally. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, (i) statements by Carmen Bozic, M.D., and Michael R. Rickels, M.D., M.S., in this press release, (ii) plans, expectations for, and the potential benefits of zimislecel, (iii) expectations for the Phase 1/2/3 clinical trial for zimislecel, including expectations for the trial to complete enrollment and dosing, and (iv) plans for potential regulatory submissions next year. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's research and development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy, that timelines for regulatory submissions may be longer than anticipated, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Vertex will host an investor event on Friday, June 20, 2025, at 7:15 p.m. CT/8:15 p.m. ET, in Chicago, to discuss the positive zimislecel data in type 1 diabetes. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section of Vertex's website at An archived webcast will be available on the company's website.
Yahoo
an hour ago
- Yahoo
Rocket Lab Stock Soars Ahead of High-Stakes Launch
Rocket Lab (NASDAQ:RKLB) shares climbed about 6% on Friday, boosted by optimism around its upcoming mission and strong contract momentum. Warning! GuruFocus has detected 7 Warning Signs with MSTR. The company plans to launch its next Electron rocket, dubbed Symphony In The Stars, on June 20 from its New Zealand site. The flight is one of two missions awarded by a private commercial client, adding to confidence in Rocket Lab's ability to secure repeat business on accelerated timelines. Market watchers often view timely launch execution as a sign of operational strength. Rocket Lab's growing cadence of missions has helped build investor confidence, particularly among retail traders, who tend to rally around launches with the potential to support future revenue streams. Analysts have pointed to the company's financial performance as another driver of sentiment. For the first quarter of 2025, Rocket Lab reported revenue of around $122.6 million, marking a year-over-year increase of more than 30%. Though the firm remains in investment mode, investors are focusing on top-line growth and expansion into adjacent offerings such as spacecraft components and orbital services. Technical indicators ahead of the launch may have contributed to the rally, alongside a broader uptick in space-related stocks. The small-satellite launch sector continues to attract interest from both government and commercial players, with Rocket Lab seen as one of the more active names in the segment. Shares were last up around 6% in afternoon trading, tracking toward their highest level in over a month. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
an hour ago
- Miami Herald
Tony Robbins sends strong message to Americans on 401(k)s
Many Americans preparing for retirement through savings and investments often encounter significant financial hurdles as they work toward a secure and enjoyable future. They eventually come to realize that while Social Security provides a foundational stream of income, it was never designed to fully support every cost of living throughout the entirety of retirement. According to renowned motivational speaker and author Tony Robbins, although 401(k) plans offer valuable opportunities, workers frequently encounter scenarios that could jeopardize their long-term financial well-being. Don't miss the move: Subscribe to TheStreet's free daily newsletter Regularly contributing to retirement accounts that offer tax advantages - such as 401(k) plans and Individual Retirement Accounts (IRAs) - is a smart financial strategy. Taking full advantage of these contributions, particularly with regard to 401(k) plans when an employer match is available, can greatly enhance retirement savings over the long term. Robbins has emphasized the importance of financial awareness when it comes to retirement planning. One of his key messages is a warning to American workers regarding misconceptions about Social Security and 401(k) plans. Related: Jean Chatzky sends strong message to Americans on Social Security A crucial part of effective retirement planning certainly involves understanding how Social Security benefits are determined and carefully choosing when to begin claiming them. By postponing benefits beyond one's full retirement age, retirees can receive higher monthly payouts from the program. Considering this background, Robbins highlights a critical caution about how 401(k) plans are used - urging workers to avoid common pitfalls that could affect their financial futures. Tony Robbins points out that for three decades, companies managing 401(k) plans were not required to reveal how much they were charging in fees. Now that disclosure is mandatory, he believes many providers hide those costs in lengthy, complex documents - making it hard for individuals to truly grasp what they're paying and keeping them largely uninformed. "What the majority of Americans don't realize is that an increase in 1% in fees will cost you 10 years in retirement income," Robbins wrote. More on retirement: Dave Ramsey offers urgent thoughts about MedicareJean Chatzky shares major statement on Social SecurityTony Robbins has blunt words on IRAs,401(k)s Robbins uses a straightforward hypothetical scenario to underscore the long-term impact of investment fees on retirement savings. In his example, three employees - let's call them Employee 1, Employee 2, and Employee 3 - each invest $100,000 at age 35 into separate mutual funds. All three investments generate the same steady annual return of 8%, and none of them withdraw any funds for 30 years. However, each employee is subject to a different annual fee: 1%, 2%, and 3%, respectively. By the time they reach age 65, Robbins clarifies, the variation in fees has created a striking difference in their account balances. Despite identical contributions and returns, Employee 1, who paid the lowest fee, has nearly double the retirement savings of Employee 3, who paid the highest. Related: Dave Ramsey sends strong message to Americans on Medicare Robbins emphasizes that the cost of high investment fees doesn't end at retirement. Using the scenario of each employee needing $60,000 annually to fund their retirement, he notes that the long-term consequences become even clearer. The employee facing the highest fees - Employee 3 - depletes their savings before reaching 75, while Employee 1, who paid the lowest fees, sees their nest egg last until age 95. According to Robbins, this stark contrast demonstrates how even small differences in fees can compound into significant financial disparities. It's a powerful reminder, he says, that being mindful of investment costs isn't just a matter of saving money - it's a crucial step in safeguarding long-term financial security. "I learned about these abuses while writing 'Money: Master the Game,' and it made me so angry that people were getting robbed blind," Robbins wrote. "So I brought in America's Best 401(k)." America's Best 401(k) is a retirement plan provider that says it aims to reduce the high fees commonly associated with traditional 401(k) plans. Robbins asked the firm to asses the 401(k) plan used by his own research company and ended up using their proposed solution. "They showed me that we were paying 276% more than we needed to for the same exact stocks," Robbins wrote. "It saved my employees $5 million in their retirement, and it cost nothing." Related: Shark Tank's Kevin O'Leary warns Americans on 401(k)s The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
